TRACON Pharmaceuticals, Inc.
Other OTCTotal Valuation
TRACON Pharmaceuticals, Inc. carries a market capitalization of 109,725.00, placing it among publicly traded companies globally. Its enterprise value stands at -3.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 109,725.00 |
| Enterprise Value | -3.62M |
Share Statistics
TRACON Pharmaceuticals, Inc. currently has 3.41M shares outstanding.
| Shares Outstanding | 3.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
TRACON Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 0.51. The price-to-sales ratio is 0.83, and the price-to-book ratio stands at -0.01.
| PE Ratio | 0.51 |
| PS Ratio | 0.83 |
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.86 |
| P/FCF Ratio | 0.29 |
| P/OCF Ratio | 0.29 |
Financial Position
TRACON Pharmaceuticals, Inc. maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.66 |
| Quick Ratio | 0.63 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -11.33 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 53.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -2.33 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
TRACON Pharmaceuticals, Inc.'s stock has declined approximately -67.8% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -67.8% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.04 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, TRACON Pharmaceuticals, Inc. generated 3.20M in revenue and converted that into 5.20M in net income, yielding earnings per share of 3.14. EBITDA reached -6.90M, while operating income came in at -6.93M.
| Revenue | 3.20M |
| Gross Profit | N/A |
| Operating Income | -6.93M |
| Pretax Income | 5.20M |
| Net Income | 5.20M |
| EBITDA | -6.90M |
| EBIT | -6.93M |
| Earnings Per Share (EPS) | 3.14 |
Balance Sheet
Total book value stands at -246.50M, with working capital of -3.38M providing operational flexibility.
| Cash & Cash Equivalents | 6.27M |
| Total Debt | N/A |
| Net Debt | -6.27M |
| Equity (Book Value) | -246.50M |
| Book Value Per Share | -148.91 |
| Working Capital | -3.38M |
Cash Flow
TRACON Pharmaceuticals, Inc. produced 9.22M in operating cash flow over the past twelve months.
| Operating Cash Flow | 9.22M |
| Capital Expenditures | N/A |
| Free Cash Flow | 9.22M |
| FCF Per Share | 5.57 |
Margins
TRACON Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -216.56 and net profit margin of 162.34 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -216.56 |
| Pretax Margin | 162.34 |
| Profit Margin | 162.34 |
| EBITDA Margin | -215.72 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 179.30 |
| FCF Yield | 347.74 |
Stock Splits
TRACON Pharmaceuticals, Inc.'s most recent stock split took place on April 10, 2024 with a 20:1 split ratio.
| Last Split Date | 4/10/2024 |
| Split Ratio | 20:1 |
Scores
TRACON Pharmaceuticals, Inc. posts an Altman Z-Score of -49.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -49.69 |